Notoginsenoside R1 (Sanchinoside R1) has been shown to exhibit antioxidant, antiapoptotic, anti-inflammatory, and immune-stimulatory properties.

METHODS: Human colorectal cancer cells HCT-116 were treated with Notoginsenoside R1 (75-300 µM) for 48 h. Cell viability was measured by MTT assay.
RESULTS: Cell viability of HCT-116 cells treated with 75-300 µM Notoginsenoside R1 was not significantly different from that of the control. However, treatment with 500 µM Notoginsenoside R1 for 48 h resulted in a significant decrease in cell viability (58±7.26%) compared to control cells. [1]
METHODS: Human coronary artery smooth muscle cells hCASMC were treated with Notoginsenoside R1 (10 µM) for 24 h. The cells were stimulated with 10% FBS for 0-30 min, and the expression levels of target proteins were detected by Western Blot.
RESULTS: Akt phosphorylation in hCASMCs was rapidly reduced in a time- and dose-dependent manner after Notoginsenoside R1 treatment, but no effect on ERK1/2 and JNK signaling was observed. notoginsenoside R1 caused a modest reduction in p38 MAPK phosphorylation, but this did not reach significance. [2]

METHODS: To study the effect on neoplastic endothelial hyperplasia, Notoginsenoside R1 (10 mg/kg) was administered intraperitoneally to C57BL/6 J mice once daily for three weeks. A mouse femoral artery injury model was subsequently performed.
RESULTS: Notoginsenoside R1 attenuated neointimal formation after femoral artery injury in vivo.Notoginsenoside R1 treatment reduced neointimal formation by inhibiting VSMC proliferation. [2]